GlassScriptPhysician profile
Christopher Lee Young
NPI 1568817336
$5,913.87
in general payments reported to CMS, 2019-2025
24 companies · $3,155 in 2025
The $3,155 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $863 · 2024: $1,897 · 2025: $3,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,913.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,671.04 | 2023-2025 | Rinvoq, Skyrizi, Mavyret |
| Genzyme Corporation | $707.85 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $655.80 | 2024-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $620.49 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $607.68 | 2023-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.20 | 2023-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $233.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $215.34 | 2023-2025 | Ibsrela |
| Pfizer INC. | $162.75 | 2024-2025 | |
| Celltrion USA INC. | $97.82 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $90.26 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $77.76 | 2024-2025 | Voquezna |
| Celgene Corporation | $74.43 | 2024 | Zeposia |
| Medtronic, INC. | $74.07 | 2025 | Nexpowder, Eleview |
| Braintree Laboratories, INC. | $56.65 | 2023 | Suflave |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $38.72 | 2024-2025 | |
| Daiichi Sankyo INC. | $29.07 | 2024 | Injectafer |
| Echosens North America, INC. | $24.93 | 2024 | Fibroscan |
| Organon LLC | $21.50 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.64 | 2025 | Iqirvo |
| Lilly USA, LLC | $20.59 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $19.31 | 2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $17.60 | 2023 | |
| Fresenius Kabi USA, LLC | $12.75 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.